Peptide receptor radionuclide therapy or everolimus in metastatic neuroendocrine tumours: SeqEveRIV study, from the GTE/ENDOCAN-RENATEN network

Through the publication of the SeqEveRIV study in J Nucl Med, I would like to congratulate Aureline Fosse who did the work for its diploma of Doctor (MD), the Hospices Civils de Lyon (HCL) team (the nuclear medicine physician Boumediene Lachachi and the oncologist Alice Durand), the GTE and the Endocan-Renaten network (Galina Jepiral, Julien Hadoux, Paul Girot, Beron A, Pauline Afchain, Cottereau AS, Eric Baudin, Dierickx LO, Thierry Lecomte, Marine Perrier, Come Lepage, Karine Bouhier-Leporrier, Bernard Goichot) and the French patient’s association (APTED).

Fosse A, Hadoux J, Girot P, Beron A, Afchain P, Cottereau AS, Baudin E, Dierickx LO, Lecomte T, Perrier M, Lepage C, Bouhier-Leporrier K, Goichot B, Lachachi B, Walter T, Durand A. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. J Nucl Med. 2024 Aug 1:jnumed.123.267363. doi: 10.2967/jnumed.123.267363. Online ahead of print. PMID: 39089810